Tradestie Institutional Equity Comparison Engine

ACHV vs EQ โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACHV Overall Edge

ACHV Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Achieve Life Sciences, Inc. (ACHV) driven by superior Momentum & Technical, Options & Structure while EQ counters with relative strength in Valuation. Fundamentally, ACHV trades at 35.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EQ at 1.5x Forward P/E and 0.0% operating margin (-52.3% YoY). In options structure, ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro) against EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner EQ
ACHV 35.3x vs EQ 1.5x Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -52.3%
Momentum & Technical Winner ACHV
1Y +43.0% vs +12.0% ยท 52W Pos 69% vs 11%
Options & Structure Winner ACHV
BREAKOUT (23rd %ile IV) vs UNCLASSIFIED (100th %ile IV)
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
1M Return -8.5%
1Y Return +43.04%
Forward P/E 35.3x
Unified AI Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
1M Return -21.13%
1Y Return +12.0%
Forward P/E 1.5x
Unified AI Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACHV +43.04% EQ +12.0% Spread: +6.58 pp (ACHV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ACHV TTM Op. Margin: 0.0% EQ TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs EQ. Trailing 12-month operating profitability (ACHV 0.0% vs EQ 0.0%) and valuation multiples (ACHV 35.3x vs EQ 1.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACHV (5) vs EQ (3)
Institutional Metric ACHV EQ Criterion Row Winner
Market Capitalization Scale $692.8M $90.6M Larger Scale ACHV
Trailing P/E Ratio Valuation 35.3x 1.5x Lower Multiple EQ
Forward P/E Ratio Valuation 35.3x 1.5x Lower Multiple EQ
Revenue Growth (YoY) Growth +0.0% -52.3% Higher Growth ACHV
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -845.0% -59.0% Higher ROE EQ
52-Week Range Position Momentum 69% ($3โ€“$9) 11% ($1โ€“$4) Stronger Trend ACHV
Beta / 30D Volatility Risk Regime 1.73ฮฒ ยท 62% Vol 1.53ฮฒ ยท 93% Vol Lower Realized Risk ACHV
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite ACHV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACHV vs EQ Buy Guide
ACHV BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ACHV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live EQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACHV nor EQ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.